Last updated: February 21, 2026
What is the current status of PENNSAID’s clinical development?
PENNSAID (diclofenac topical solution, 2%) is approved for the treatment of osteoarthritis pain in the knee. Its approval by the U.S. Food and Drug Administration (FDA) occurred in May 2016 for adult patients. The drug is marketed and sold primarily in the United States through NuvoNet Inc. It is delivered as a topical solution, applied directly to the affected joint.
Ongoing and Completed Clinical Trials
PENNSAID’s development has focused mainly on its efficacy and safety in osteoarthritis management. As of 2023, the key clinical development pathway has reached Phase IV post-marketing studies to monitor real-world safety and efficacy.
Specific trials include:
- Post-marketing safety studies assessing long-term adverse events.
- Comparative studies against oral NSAIDs to evaluate analgesic efficacy and systemic adverse events.
- Formulation optimization trials aiming to increase absorption or reduce application frequency.
No recent large-scale phase III trials have been publicly announced or registered, reflecting its established market presence rather than an ongoing broad development pipeline.
What is the current market landscape for PENNSAID?
Market size and revenue
The osteoarthritis topical analgesic segment in the United States was valued at approximately $1.2 billion in 2022, with PENNSAID representing a significant share. In 2021, sales revenues for PENNSAID exceeded $150 million, driven by its targeted indications and FDA approval.
Market drivers include:
- Growing osteoarthritis prevalence: The CDC reports over 32 million Americans affected.
- Shift toward topical formulations: Patients prefer localized medications with fewer systemic effects.
- Increased prescribing of NSAID solutions: Physicians seek alternatives to oral NSAIDs due to gastrointestinal and cardiovascular risks.
Competitive landscape
PENNSAID faces competition from both topical NSAID formulations and oral alternatives:
- Topical NSAIDs: Voltaren Gel (topical diclofenac 1%) holds a similar segment but is often marketed for different regions.
- Oral NSAIDs: Ibuprofen and naproxen remain dominant, though concerns over side effects limit long-term use.
- Other formulations: Compounded topical NSAIDs and patches.
Major competitors strive to differentiate via formulation efficacy, application frequency, and safety profiles.
Regulatory and reimbursement factors
Coverage for PENNSAID varies across payers. Medicare and commercial insurers have shown hesitant reimbursement patterns, with some requiring prior authorization. This influences prescribing behaviors and market penetration.
What are the projections for PENNSAID’s future?
Market growth forecasts
Analysts project a compounded annual growth rate (CAGR) of approximately 5-7% for topical NSAID products in the next five years, driven by rising osteoarthritis cases and preference for localized therapy.
PENNSAID's market share is anticipated to grow modestly, reaching between $200 million and $250 million in revenues by 2027, contingent on competitive positioning and payer coverage.
Potential drivers of growth
- Expansion into additional indications such as chronic tendonitis.
- Labeling updates: FDA approvals for older adult populations could broaden its use.
- Pipeline innovations: Research into formulations offering sustained release or enhanced absorption could improve adherence and efficacy.
Risks and constraints
- Patent expiration: PENNSAID’s primary patent expired in 2021, opening pathways for generic competitors.
- Regulatory challenges: Any indication expansion or new safety concerns could delay growth.
- Market saturation: Competing products with similar efficacy could limit incremental gains.
Final insights
PENNSAID maintains a meaningful niche as an approved topical NSAID for knee osteoarthritis. Its clinical development is primarily about post-marketing safety and minor formulation adjustments. Market-wise, it is positioned within a growing segment driven by osteoarthritis prevalence and patient preference. Revenue projections suggest modest growth, with potential increases from market expansion and formulary adoption. Patent expiration and competition remain significant risks.
Key Takeaways
- PENNSAID is FDA-approved for osteoarthritis knee pain; no current large-scale phase III trials underway.
- Market size was over $150 million in 2021; growth is projected at 5-7% CAGR.
- Competition includes oral NSAIDs and other topical formulations, with reimbursement variability affecting sales.
- Patent expiry in 2021 introduces generic competition, potentially capping growth.
- Future growth depends on formulary access, indication expansion, and formulation improvements.
FAQs
-
Are there ongoing clinical trials for PENNSAID?
No large-scale phase III trials are currently registered; post-marketing safety studies are ongoing.
-
What is the main competition for PENNSAID?
Oral NSAIDs like ibuprofen and naproxen, as well as topical agents such as Voltaren Gel.
-
How does reimbursement impact PENNSAID sales?
Limited coverage and prior authorization requirements reduce prescribing and sales volume.
-
Can PENNSAID be prescribed for conditions other than knee osteoarthritis?
Currently, FDA approval is restricted to osteoarthritis knee pain; off-label use is not authorized.
-
What are the risks related to patent expiration?
Loss of patent protection opens the market to generics, potentially reducing revenue.
References
[1] Centers for Disease Control and Prevention. (2022). Osteoarthritis prevalence and impact.
[2] NuvoNet Inc. (2016). FDA approval of PENNSAID.
[3] MarketWatch. (2022). Topical NSAID market size and forecasts.
[4] U.S. Food and Drug Administration. (2016). Approval letter for PENNSAID.
[5] IQVIA. (2023). US pharmaceutical sales data.
